Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice.

Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grüngreiff K, König I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J; German Anti-D Study Group.

Gastroenterology. 2010 Nov;139(5):1586-92, 1592.e1. doi: 10.1053/j.gastro.2010.07.005. Epub 2010 Jul 14.

PMID:
20637200
2.

Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.

Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Foung SK, Pécheur EI, Pietschmann T.

J Virol. 2010 Jun;84(11):5751-63. doi: 10.1128/JVI.02200-09. Epub 2010 Mar 31.

3.

Ribavirin improves early responses to peginterferon through improved interferon signaling.

Feld JJ, Lutchman GA, Heller T, Hara K, Pfeiffer JK, Leff RD, Meek C, Rivera M, Ko M, Koh C, Rotman Y, Ghany MG, Haynes-Williams V, Neumann AU, Liang TJ, Hoofnagle JH.

Gastroenterology. 2010 Jul;139(1):154-62.e4. doi: 10.1053/j.gastro.2010.03.037. Epub 2010 Mar 17.

4.

HCV genetic elements determining the early response to peginterferon and ribavirin therapy.

Enomoto N, Maekawa S.

Intervirology. 2010;53(1):66-9. doi: 10.1159/000252787. Epub 2010 Jan 5.

PMID:
20068344
5.

The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis.

Magiorkinis G, Magiorkinis E, Paraskevis D, Ho SY, Shapiro B, Pybus OG, Allain JP, Hatzakis A.

PLoS Med. 2009 Dec;6(12):e1000198. doi: 10.1371/journal.pmed.1000198. Epub 2009 Dec 15.

6.

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M.

Nature. 2009 Oct 8;461(7265):798-801. doi: 10.1038/nature08463.

7.

Hepatitis C virus: viral proteins on the move.

McLauchlan J.

Biochem Soc Trans. 2009 Oct;37(Pt 5):986-90. doi: 10.1042/BST0370986. Review.

PMID:
19754437
8.

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J.

Nat Genet. 2009 Oct;41(10):1100-4. doi: 10.1038/ng.447. Epub 2009 Sep 13.

PMID:
19749758
9.

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB.

Nature. 2009 Sep 17;461(7262):399-401. doi: 10.1038/nature08309. Epub 2009 Aug 16.

PMID:
19684573
10.

Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.

Yuan HJ, Jain M, Snow KK, Gale M Jr, Lee WM; HALT-C Trial Group.

J Viral Hepat. 2010 Mar;17(3):208-16. doi: 10.1111/j.1365-2893.2009.01169.x. Epub 2009 Jul 28.

11.

Diagnosis, management, and treatment of hepatitis C: an update.

Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases.

Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759. No abstract available.

PMID:
19330875
12.

Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.

Xu J, Liu S, Xu Y, Tien P, Gao G.

Virus Res. 2009 Apr;141(1):55-62. doi: 10.1016/j.virusres.2009.01.001. Epub 2009 Jan 29.

PMID:
19185598
13.

Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans.

Aurora R, Donlin MJ, Cannon NA, Tavis JE.

J Clin Invest. 2009 Jan;119(1):225-36. doi: 10.1172/JCI37085. Epub 2008 Dec 22.

14.

Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.

von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H, Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S.

Hepatology. 2008 Nov;48(5):1404-11. doi: 10.1002/hep.22483.

PMID:
18846541
15.

Detecting causal nonlinear exposure-response relations in epidemiological data.

Cox LA Jr.

Dose Response. 2006 Aug 19;4(2):119-32. doi: 10.2203/dose-response.05-002.Cox.

16.

Coordinated evolution of the hepatitis C virus.

Campo DS, Dimitrova Z, Mitchell RJ, Lara J, Khudyakov Y.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9685-90. doi: 10.1073/pnas.0801774105. Epub 2008 Jul 9.

17.

Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles.

Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, Date T, Matsuura Y, Miyamura T, Wakita T, Suzuki T.

J Virol. 2008 Aug;82(16):7964-76. doi: 10.1128/JVI.00826-08. Epub 2008 Jun 4.

18.

Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.

Cannon NA, Donlin MJ, Fan X, Aurora R, Tavis JE; Virahep-C Study Group.

PLoS One. 2008 May 7;3(5):e2123. doi: 10.1371/journal.pone.0002123.

19.

Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.

Muñoz de Rueda P, Casado J, Patón R, Quintero D, Palacios A, Gila A, Quiles R, León J, Ruiz-Extremera A, Salmerón J.

J Virol. 2008 Jul;82(13):6644-53. doi: 10.1128/JVI.02231-07. Epub 2008 Apr 30.

20.

Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly.

Appel N, Zayas M, Miller S, Krijnse-Locker J, Schaller T, Friebe P, Kallis S, Engel U, Bartenschlager R.

PLoS Pathog. 2008 Mar 28;4(3):e1000035. doi: 10.1371/journal.ppat.1000035.

Supplemental Content

Support Center